期刊
ONCOLOGIST
卷 27, 期 4, 页码 E340-E349出版社
OXFORD UNIV PRESS
DOI: 10.1093/oncolo/oyac024
关键词
nasopharyngeal carcinoma; Epstein-Barr virus; BART8-3p; biomarker; metastasis
类别
资金
- Startup Fund for Scientific Research, Fujian Medical University [2019QH1192]
- Joint Funds for the Innovation of Science and Technology of Fujian Province [2019Y9037]
- Natural Science Foundation of Fujian Province [2020J05071]
- National Natural Science Foundation of China [81972717]
- Joint Funds for the Innovation of Science and Technology, Fujian Province [2018Y9114]
- Joint Research Project of Health and Education of Fujian Province [2019-WJ-02]
Plasma BART8-3p is a promising biomarker for the detection and prognosis of nasopharyngeal carcinoma (NPC), as high levels of BART8-3p are associated with worse overall survival, distant metastasis-free survival, and locoregional relapse-free survival.
Background Nasopharyngeal carcinoma is an Epstein-Barr virus (EBV)-associated tumor that is highly common in southern China. Our previous sequencing data demonstrated that the EBV-encoded microRNA BART8-3p was most upregulated in nasopharyngeal carcinoma (NPC) and was closely associated with the metastasis of NPC. However, the values of plasma BART8-3p in NPC patients have not yet been well characterized. Material and Methods We quantified plasma BART8-3p expression by quantitative real-time PCR in 205 newly diagnosed NPC patients. Kaplan-Meier analysis was used to compare overall survival (OS), distant metastasis-free survival (DMFS), and locoregional relapse-free survival (LRRFS) between the groups. Results Plasma pretreatment BART8-3p was highly expressed in NPC patients compared with healthy controls. Pretreatment BART8-3p yielded a 92% predictive value for detecting NPC. Importantly, BART8-3p decreased dramatically after therapy relative to pretreatment levels. High levels of pretreatment or post-treatment BART8-3p were associated with worse OS, DMFS, and LRRFS. Multivariate analysis showed that high pretreatment or post-treatment BART8-3p was an independent unfavorable prognostic marker for OS (HR 3.82, 95% CI 1.77-8.24, P = .001 or HR 2.74, 95% CI 1.27-5.91, P = .010), DMFS (HR 2.82, 95% CI 1.36-5.85, P = .005 or HR 3.27, 95% CI 1.57-6.81, P = .002), and LRRFS (HR 1.94, 95% CI 1.12-3.35, P = .018 or HR 2.03, 95% CI 1.14-3.62, P = .016) in NPC. Subgroup analysis revealed that for patients with locally advanced NPC with high levels of pretreatment BART8-3p (n = 58), more cycles of chemotherapy (>= 6 cycles) tended to prolong OS (P = .070). Over 50% (6/11) patients with high levels of post-treatment BART8-3p presented distant metastasis. Conclusion Plasma BART8-3p is a promising biomarker for the detection and prognosis of NPC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据